Krystal Biotech, Inc. (KRYS) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 12/20/23
Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)GlobeNewsWire • 12/19/23
Wall Street Analysts See a 42.55% Upside in Krystal Biotech, Inc. (KRYS): Can the Stock Really Move This High?Zacks Investment Research • 12/05/23
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis BullosaGlobeNewsWire • 11/27/23
Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/06/23
Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023GlobeNewsWire • 10/30/23
Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines ConferenceGlobeNewsWire • 09/28/23
Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin DeficiencyGlobeNewsWire • 09/21/23
Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceGlobeNewsWire • 09/07/23
Krystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin DeficiencyGlobeNewsWire • 09/05/23
Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational HighlightsGlobeNewsWire • 08/07/23
Krystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707GlobeNewsWire • 07/26/23
Krystal Biotech, Inc. (KRYS) is on the Move, Here's Why the Trend Could be SustainableZacks Investment Research • 07/17/23
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic FibrosisGlobeNewsWire • 07/03/23